Printer Friendly

Enigma Biomedical, Invicro Ink MOU to Co-Develop Synaptic Density Biomarker Imaging.

M2 PHARMA-September 24, 2018-Enigma Biomedical, Invicro Ink MOU to Co-Develop Synaptic Density Biomarker Imaging

(C)2018 M2 COMMUNICATIONS

- Canada-based molecular imaging and medicine specialist Enigma Biomedical Group has inked a collaboration agreement with US-based Invicro, a Konica Minolta company and a provider of imaging services and software for research and drug development, to cooperate in the development of Synaptic Density Biomarker Imaging, the company said.

SDI promises to provide an important new tool in understanding neurodegenerative diseases such as Alzheimer's and other dementias.

As part of the agreement, both parties will contribute their respective SDI-related assets and competencies to provide the pharmaceutical industry access to this unique imaging tool as well as specific informatics and analytics capabilities.

Enigma will hold the various commercial and distribution licenses and be responsible for development and global tracer access whereas Invicro will focus on informatics solutions for better interpretation of this cutting-edge biomarker technology.

Use of this biomarker platform is an additional approach to supporting development of disease-modifying therapies for neurodegenerative disorders.

Toronto-based Enigma Biomedical Group enhances access to key technologies with a focus on molecular imaging and medicine.

EBG offers a suite of services to the pharmaceutical industry and clinical research community to accelerate drug development and global access. EBG partners with academic institutions and universities to foster and broaden access to novel research.

Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau's vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer's disease and is currently focused on the development of the MK-6240 Tau Imaging biomarker.

Meilleur Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group.

Cerveau's vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer's disease and is currently focused on the research applications of the NAV-4694 Amyloid Imaging biomarker.

With headquarters in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas.

Invicro's multi-disciplinary team provides a range of image informatics, engineering and operational services.

Originally focused on imaging in discovery phase, in 2016 Invicro expanded its offering in clinical phase research with the acquisition of Molecular Neuroimaging, LLC, followed by the acquisition of Imanova and CORE Clinical in 2017.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 24, 2018
Words:406
Previous Article:Mebias Discovery Receives Grant from NIDA to Advance Its Signaling-Pathway Selective Mu-Opioid Receptor Drug Candidate.
Next Article:Foundation Medicine Introduces FoundationOneLiquid Liquid Biopsy Test for Solid Tumors in Patients with Advanced Cancer.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters